Highlights

• Scancell unveiled a merger agreement with a Nasdaq-listed biotechnology company alongside a major financing package to support its next clinical stage.
• The combined business plans to maintain its London market presence while adding a Nasdaq listing under a new trading symbol.
• The transaction is designed to strengthen funding for a late-stage cancer immunotherapy programme and broaden access to the US life sciences market.

The UK stock market continues to witness strategic activity from innovative biotechnology businesses seeking broader international exposure. Scancell Holdings plc (LSE:SCLP), a UK-based biotechnology company focused on cancer immunotherapies, has announced a merger with US-listed Neuphoria Therapeutics alongside a sizeable financing package. The development highlights growing cross-border activity within the UK's AIM Stocks and healthcare sector as companies look to accelerate clinical development while expanding access to global capital markets.

A transformational merger takes centre stage

Scancell has entered into an all-share merger agreement with Neuphoria Therapeutics, creating a combined biotechnology business that intends to operate under the Scancell name following completion of the transaction.

As part of the proposed combination, the enlarged company plans to retain its existing London market presence while also seeking admission to Nasdaq. The dual-market strategy is expected to increase visibility across international healthcare markets while strengthening the company's position among global biotechnology peers.

The transaction remains subject to customary approvals, including consent from shareholders of both companies before it can be completed.

Dual-market strategy broadens global reach

A Nasdaq listing represents a significant strategic step for the enlarged group. The US remains one of the world's largest biotechnology funding markets, providing access to specialist healthcare-focused capital and a wider institutional audience.

Maintaining its London listing while establishing a Nasdaq presence also allows the business to preserve its UK market identity while extending its international profile. This approach reflects a growing trend among biotechnology companies seeking broader market participation without abandoning their domestic shareholder base.

Financing package supports clinical ambitions

Alongside the merger announcement, Scancell outlined an extensive financing plan intended to provide financial support for its next stage of development.

The package combines several funding sources, including private investment commitments, a UK placing, a retail offer and proposed debt financing. In addition, the merger is expected to contribute existing cash resources from Neuphoria Therapeutics, strengthening the combined balance sheet following completion.

The company also confirmed that a previously released announcement required corrections relating to the expected pro forma cash balance and the aggregate proceeds from the private placement. The revised statement clarified those figures while leaving all other transaction details unchanged.

Focus remains firmly on cancer immunotherapy

The enlarged business will continue concentrating on targeted, off-the-shelf active immunotherapies designed to treat cancer.

Its lead clinical programme, iSCIB1+, remains the central asset within the combined portfolio. The therapy is being evaluated for advanced melanoma and has already progressed through important clinical development milestones.

Management believes the latest transaction creates the financial foundation required to advance the programme into a global registrational study, marking an important stage in its long-term development pathway.

Late-stage programme drives strategic direction

The company's clinical strategy centres on progressing iSCIB1+ through the next phase of regulatory development.

According to the announcement, previous clinical findings have demonstrated encouraging durability and effectiveness in combination with established immunotherapy treatments. Additional clinical updates are expected over the coming period as the programme continues to advance.

The financing package is intended to provide sufficient resources to support this late-stage development programme while extending operational funding through key clinical milestones.

Why the US market matters

For biotechnology businesses, access to the US capital market often provides greater visibility among specialist healthcare participants and larger funding pools.

Nasdaq has long been recognised as one of the world's leading exchanges for biotechnology companies, hosting many established pharmaceutical innovators alongside emerging life sciences businesses.

By combining with an existing Nasdaq-listed company, Scancell gains a direct route into this market while maintaining continuity for existing UK shareholders.

The strategy also reflects the increasingly international nature of biotechnology development, where funding, research collaboration and commercial opportunities frequently span multiple regions.

Merger creates a broader biotechnology platform

Beyond the financing benefits, the transaction also combines complementary corporate structures into a single organisation.

The enlarged business is expected to continue operating under the Scancell brand while integrating Neuphoria Therapeutics into its wider development strategy.

This combination creates a broader biotechnology platform capable of advancing multiple clinical objectives while leveraging enhanced market access and financial flexibility.

Corrected announcement strengthens transparency

The latest regulatory release primarily addressed two numerical corrections contained within the original merger announcement.

The amended version revised the expected pro forma cash balance following completion of the planned US listing transactions and updated the stated proceeds associated with the private placement.

Importantly, the strategic rationale, transaction structure and financing framework remain unchanged, with the company confirming that all other details continue to apply.

Healthcare sector continues to evolve

The transaction reflects broader trends across the UK biotechnology landscape, where companies continue exploring international partnerships and funding opportunities to advance innovative therapies.

Cross-border mergers, dual-market listings and diversified financing structures have become increasingly common within the healthcare industry as clinical programmes become more capital intensive.

For businesses developing advanced immunotherapies, securing sufficient long-term funding remains essential to progressing treatments through large-scale clinical studies and regulatory review.

What comes next

Completion of the merger remains dependent upon shareholder approval together with the satisfaction of customary transaction conditions.

If approved, the enlarged company intends to proceed with its Nasdaq listing plans while continuing to advance its lead immunotherapy programme through the next stage of clinical development.

The accompanying financing package is designed to provide the operational resources needed for these objectives while reinforcing the company's international growth strategy.

Scancell's proposed merger with Neuphoria Therapeutics represents a significant strategic milestone for the UK biotechnology company. By combining a dual-market listing strategy with a comprehensive financing package, the enlarged group aims to strengthen its international presence while supporting the continued development of its cancer immunotherapy pipeline. Although the latest regulatory update corrected selected financial figures from the original announcement, the overall transaction strategy remains unchanged, keeping the focus firmly on advancing late-stage clinical development and expanding global market access.